Tenax Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Chris Giordano

İcra Kurulu Başkanı

US$644.8k

Toplam tazminat

CEO maaş yüzdesi	62.9%
CEO görev süresi	3.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Sep 15

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Jan 20

CEO Tazminat Analizi

Chris Giordano'un ücretlendirmesi Tenax Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$13m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$645k	US$405k	-US$8m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$667k	US$386k	-US$11m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	US$861k	US$183k	-US$32m

Tazminat ve Piyasa: Chris 'ın toplam tazminatı ($USD 644.77K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 654.40K ).

Tazminat ve Kazançlar: Chris 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Chris Giordano (50 yo)

3.3yrs

Görev süresi

US$644,770

Tazminat

Mr. Christopher T. Giordano, also known as Chris, has been the Chief Executive Officer and Director of Tenax Therapeutics, Inc. since joining on July 14, 2021 and serves as its President since October 29,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Giordano	CEO, President & Director	3.3yrs	US$644.77k	Veri yok
Stuart Rich	Chief Medical Officer & Director	3.8yrs	US$481.22k	0.043% $ 6.5k
Lawrence Hoffman	Interim Chief Financial Officer	less than a year	Veri yok	Veri yok
Doug Randall	Executive Vice President of Commercial & Business Operations	no data	Veri yok	Veri yok
Douglas Hay	Senior Vice President of Regulatory Affairs	no data	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim: TENX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Giordano	CEO, President & Director	3.3yrs	US$644.77k	Veri yok
Stuart Rich	Chief Medical Officer & Director	3.8yrs	US$481.22k	0.043% $ 6.5k
Gerald Proehl	Independent Chairman	10.6yrs	US$88.50k	0.049% $ 7.5k
Michael Davidson	Independent Director	3.8yrs	US$57.50k	0.085% $ 12.9k
Daniel Burkhoff	Member of PH-Left Heart Disease Scientific Advisory Board	6.8yrs	Veri yok	Veri yok
Declan Doogan	Independent Director	3.8yrs	US$48.50k	0.067% $ 10.2k
Robyn Hunter	Independent Director	2.8yrs	US$65.00k	0% $ 0
June Almenoff	Independent Director	3.8yrs	US$59.50k	0% $ 0
Sanjiv Shah	Member of PH-Left Heart Disease Scientific Advisory Board	6.8yrs	Veri yok	Veri yok
Barry Borlaug	Member of PH-Left Heart Disease Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
Robert Frantz	Member of PAH Scientific Advisory Board	no data	Veri yok	Veri yok
Anna Hemnes	Member of PAH Scientific Advisory Board	no data	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TENX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Tenax Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Tenax Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer

Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Announces Resignation of Executives

High number of new and inexperienced directors

Recent updates

New minor risk - Profitability

Tenax Therapeutics, Inc. announced that it has received $99.681169 million in funding from a group of investors

Tenax Therapeutics, Inc. announced that it expects to receive $99.681169 million in funding from a group of investors

New minor risk - Share price stability

Tenax Therapeutics, Inc. announced that it expects to receive $99.999996 million in funding from a group of investors

New major risk - Revenue and earnings growth

Tenax Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Profitability

Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients

Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer

Tenax Therapeutics Receives Non-Compliance Notice from Nasdaq

Forecast to breakeven in 2026

Tenax Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board

Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure

New major risk - Share price stability

The Nasdaq Stock Market LLC Grants Tenax Therapeutics's Request for an Extension Through March 25, 2024 to Evidence Compliance with the $1.00 Per Share Requirement for Continued Inclusion on the Nasdaq Capital Market

Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. Receives a Notice of Allowance from the United States Patent and Trademark Office for its Patent Application

Price target increased by 16% to US$110

Tenax Receives Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Announces the Presentation of Positive Data from a Study of PH-HFpEF Patients Being Treated with Oral Levosimendan

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Tenax Therapeutics, Inc. Receives Formal Notice That the Nasdaq Stock Market LLC

Forecast to breakeven in 2023

Tenax Therapeutics, Inc. Announces Resignation of Executives

Price target decreased to US$4.00

Tenax Therapeutics, Inc. Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

Tenax Therapeutics, Inc. announced that it expects to receive $8 million in funding from Armistice Capital LLC

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Appoints Robyn Hunter to the Board of Directors

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

High number of new and inexperienced directors

Forecast to breakeven in 2022

Price target increased to US$4.75

Independent Director James Mitchum has left the company

Tenax Therapeutics, Inc. Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

High number of new directors

CEO & Director Anthony DiTonno has left the company

Independent Director Chris Rallis has left the company

Independent Director Gregory Pepin has left the company

Independent Chairman Ronald Blanck has left the company

Price target increased to US$4.75

Tenax Therapeutics, Inc. Expands Board of Directors

New 90-day high: US$2.78

Tenax Therapeutics, Inc. (NasdaqCM:TENX) acquired PH Precision Med Inc. for $21.6 million.

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

New 90-day high: US$2.36

New 90-day high: US$1.98

Tenax Therapeutics, Inc. Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020

New 90-day low: US$1.18

Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

New 90-day high: US$1.63

Price target lowered to US$4.23

Tenax Therapeutics, Inc. announced that it has received $4.735325 million in funding

Tenax Therapeutics, Inc. announced that it expects to receive $4.735325 million in funding

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş